A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology |
2023 |
NA |
NA |
NA |
NA |
Oncology |
Organoids |
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors |
2016 |
NA |
HCC827, LU1235, LU1868 |
NSCLC- Lung Cancer |
Lung Cancer |
Oncology |
CDX, PDX |
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease |
2023 |
NA |
huPKD05 |
Kidney Disease |
ADPKD |
Genetic Disease |
3D Cyst |
A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification |
2018 |
H Hanting Zhu, C Chunyu Wang, J Jingjing Wang, D Dawei Chen, J Jiaying Deng, J Jianyun Deng, J Jianhong Fan, H Harun Badakhshi, X Xuesong Huang, L Likun Zhang, J Jie Cai, S Sheng Guo, W Wubin Qian, Y Yongzhan Nie, Q Qixiang Li, K Kuaile ZhaoH Hanting Zhu , et al. |
ES0026, ES0042, ES0110, ES0136, ES0141, ES0172, ES0176, ES0178, ES0191, ES0195, ES0199, ES0201, ES0204, ES0215, ES0219, ES2116 |
ESCC - Esophageal Cancer |
Esophageal Cancer |
Oncology |
PDX |
AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes |
2016 |
NA |
AM7577 |
M5 - Acute Myeloid Leukemia |
Acute Myeloid Leukemia |
Oncology |
PDX |
Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells |
2021 |
NA |
NA |
NA |
NA |
Immuno-Oncology, Inflammation |
NA |
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations |
2017 |
NA |
AM7577 |
NA |
Acute Myeloid Leukemia |
Oncology |
PDX |
Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinib |
2020 |
NA |
HCC827 |
NSCLC (EGFR hi) - Lung Cancer |
Lung Cancer |
Oncology |
CDX |
Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions |
2018 |
NA |
LU0387 |
NSCLC- Lung Cancer |
Lung Cancer |
Oncology |
PDX |
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice |
2020 |
NA |
NA |
NA |
Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian Cancer |
Oncology |
PDX, Sygeneic |
Assessing therapy response in patient-derived xenografts. |
2021 |
J Janosch Ortmann, L Ladislav Rampášek, E Elijah Tai, AS Arvind Singh Mer, R Ruoshi Shi, EL Erin L Stewart, C Celine Mascaux, A Aline Fares, NA Nhu-An Pham, G Gangesh Beri, C Christopher Eeles, D Denis Tkachuk, C Chantal Ho, S Shingo Sakashita, J Jessica Weiss, X Xiaoqian Jiang, G Geoffrey Liu, DW David W Cescon, CA Catherine A O'Brien, S Sheng Guo, MS Ming-Sound Tsao, B Benjamin Haibe-Kains, A Anna GoldenbergJ Janosch Ortmann , et al. |
NA |
NA |
NA |
NA |
NA |
Authentication, characterization and contamination detection of cell lines, xenografts and organoids by barcode deep NGS sequencing |
2020 |
NA |
NA |
NA |
NA |
NA |
CDX, Cell lines, Organoids, PDX |
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases |
2021 |
NA |
NA |
NA |
NA |
Immuno-Oncology, Inflammation |
NA |
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors |
2017 |
NA |
NA |
NA |
Bladder Cancer, Gastric Cancer, Lung Cancer |
Immuno-Oncology, Oncology |
PDX |
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature |
2016 |
S Sheng Guo, D Dawei Chen, X Xuesong Huang, J Jie Cai, JP Jean-Pierre Wery, QX Qi-Xiang LiS Sheng Guo , et al. |
CR0170, CR0193, CR0196, CR0231, CR0588, CR2110, CR2502, CR2520 |
NA |
Colorectal Cancer |
Oncology |
PDX |
Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature |
2016 |
NA |
CR0004, CR0010, CR0012, CR0024, CR0028, CR0029, CR0047, CR0133, CR11377 |
Mucinous adenocarcinoma - Gastric Cancer |
Colorectal Cancer |
Immuno-Oncology |
PDX |
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer |
2019 |
NA |
GA0060 |
NA |
Gastric Cancer |
Oncology |
PDX |
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment |
2022 |
NA |
NA |
NA |
NA |
Immuno-Oncology, Inflammation |
NA |
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification. |
2022 |
T Ting Liu, J Jianan Rao, W Wenting Hu, B Bowen Cui, J Jiaoyang Cai, Y Yuhan Liu, H Huiying Sun, X Xiaoxiao Chen, Y Yanjing Tang, J Jing Chen, X Xiang Wang, H Han Wang, W Wubin Qian, B Binchen Mao, S Sheng Guo, R Ronghua Wang, Y Yu Liu, S Shuhong ShenT Ting Liu , et al. |
NA |
NA |
NA |
Oncology |
NA |
DNA-Damage-Induced Alternative Splicing of p53 |
2021 |
J Jing Chen, D Dadong Zhang, X Xiaodi Qin, K Kouros Owzar, JJ Jennifer J McCann, MB Michael B KastanJ Jing Chen , et al. |
AD0484 |
NA - Adrenal gland Cancer, T - Acute Lymphoblastic Leukemia |
Acute Lymphoblastic Leukemia, Adrenal gland Cancer |
Immuno-Oncology |
CDX, GEMM |
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors |
2017 |
NA |
CR2518, CR2545 |
NA |
Colorectal Cancer |
Oncology |
PDX |
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells |
2017 |
NA |
NA |
NA |
Pancreatic Cancer |
Oncology |
PDX |
EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor |
2016 |
NA |
HCC827, LU0387 |
NSCLC- Lung Cancer |
Lung Cancer |
Oncology |
CDX, PDX |
EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab |
2017 |
X Xiaohong Wang, R Runjia Fu, Y Ying Hu, H Hong Du, S Shuangxi Li, Z Ziyu Li, Y Yiqiang Liu, Q Qixiang Li, L Lianhai Zhang, J Jiafu JiX Xiaohong Wang , et al. |
NA |
NA |
Gastric Cancer |
Oncology |
PDX |
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer |
2019 |
LA Louise A Koopman, MG Mikkel G Terp, GG Gijs G Zom, ML Maarten L Janmaat, K Kirstine Jacobsen, E Elke Gresnigt-van den Heuvel, M Marcel Brandhorst, U Ulf Forssmann, F Freddy de Bree, N Nora Pencheva, A Andreas Lingnau, MA Maria A Zipeto, PW Paul Whi Parren, EC Esther Cw Breij, HJ Henrik J DitzelLA Louise A Koopman , et al. |
LU0858, LU1868 |
NSCLC- Lung Cancer |
Lung Cancer |
Immuno-Oncology |
PDX |
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. |
2022 |
B Bram Herpers, B Berina Eppink, MI Mark I James, C Carme Cortina, A Adrià Cañellas-Socias, SF Sylvia F Boj, X Xavier Hernando-Momblona, D Dominik Glodzik, RC Rob C Roovers, M Marc van de Wetering, C Carina Bartelink-Clements, V Vanessa Zondag-van der Zande, JG Jara García Mateos, K Kuan Yan, L Lucia Salinaro, A Abdul Basmeleh, S Szabolcs Fatrai, D David Maussang, JJ Jeroen J Lammerts van Bueren, I Irene Chicote, G Garazi Serna, L Laia Cabellos, L Lorena Ramírez, P Paolo Nuciforo, R Ramon Salazar, C Cristina Santos, A Alberto Villanueva, C Camille Stephan-Otto Attolini, E Elena Sancho, HG Hector G Palmer, J Josep Tabernero, MR Michael R Stratton, J John de Kruif, T Ton Logtenberg, H Hans Clevers, LS Leo S Price, RGJ Robert G J Vries, E Eduard Batlle, M Mark ThrosbyB Bram Herpers , et al. |
NA |
NA |
NA |
Oncology |
Organoids |
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models |
2017 |
NA |
LU2503, LU5381 |
NSCLC- Lung Cancer |
Lung Cancer |
Immuno-Oncology, Inflammation |
PDX |
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties |
2020 |
NA |
HCC827 |
NSCLC- Lung Cancer |
Lung Cancer |
Immuno-Oncology, Oncology |
HuGEMM, MiXeno |
HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models |
2023 |
Hang Ke, Faming Zhang, Jingjing Wang, Lingxin Xiong, Xiaoyu An, Xiaolong Tu, Cen Chen, Yueying Wang, Binchen Mao, Sheng Guo, Cunxiang Ju, Xiangfei He, Ruilin Sun, Lei Zhang, Owen A. O’Connor & Qi-Xiang LiHang Ke , et al. |
huCD47-A20 B-lymphoma, Karpas-299 T-lymphoma, LY12962, LY12966, LY2264, LY2266, LY2345, LY6701, Raji B-lymphoma |
B cell lymphoma, NHL (DLBCL, ABC/GCB), T-cell Lymphoma |
Lymphoma |
Immuno-Oncology, Oncology |
CDX, HuGEMM, MiXeno, PDX, Sygeneic |
Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry |
2018 |
X Xiaoyu An, X Xuesong Ouyang, H Hui Zhang, T Tingting Li, YY Yu-Yang Huang, Z Zhiyuan Li, D Demin Zhou, QX Qi-Xang LiX Xiaoyu An , et al. |
NA |
Ductal adenocarcinoma - Pancreatic Cancer |
Pancreatic Cancer |
Oncology |
MuPrime |
In Vivo Pharmacology Models for Cancer Target Research |
2019 |
D Dawei Chen, X Xiaoyu An, X Xuesong Ouyang, J Jie Cai, D Demin Zhou, QX Qi-Xiang LiD Dawei Chen , et al. |
AD0484, AL5514, AL5518, AL5521, AL8223 |
ADC - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer |
Adrenal gland Cancer, Bladder Cancer |
Oncology |
CDX, GEMM, HuCell |
Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. |
2015 |
NA |
NA |
NA |
NA |
Oncology |
CDX, PDX |
Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models |
2017 |
B Baoan Hong, Y Yong Yang, S Sheng Guo, S Shayiremu Duoerkun, X Xiaohu Deng, D Dawei Chen, S Shijun Yu, W Wubin Qian, Q Qixiang Li, Q Qing Li, K Kan Gong, N Ning ZhangB Baoan Hong , et al. |
KI2367, KI2368 |
RCC - Kidney Cancer |
Kidney Cancer |
Oncology |
PDX |
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage |
2021 |
NA |
NA |
NA |
NA |
Oncology |
PDX |
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer |
2018 |
NA |
LU0387 |
NA |
Lung Cancer |
Oncology |
PDX |
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor |
2019 |
NA |
NA |
NA |
Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer |
Oncology |
PDX |
MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity |
2018 |
NA |
GA0055 |
ADC - Gastric Cancer |
Gastric Cancer |
Immuno-Oncology, Oncology |
PDX |
Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models |
2023 |
NA |
NA |
NA |
NA |
Oncology |
PDX |
New insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoids |
2021 |
NA |
NA |
NA |
NA |
Oncology |
Organoids |
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models |
2019 |
NA |
BL6078, SA9003, SK6005 |
NA |
Bladder Cancer, Sarcoma, Skin Cancer |
Oncology |
MuPrime |
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors |
2016 |
M Mengmeng Yang, X Xiaoxi Xu, J Jie Cai, J Jinying Ning, JP Jean Pierre Wery, QX Qi-Xiang LiM Mengmeng Yang , et al. |
LU0387, LU0858, LU1235, LU1868, LU3075 |
NSCLC- Lung Cancer |
Lung Cancer |
Oncology |
PDX |
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor |
2017 |
NA |
CR3496, CR3547, CR3612, CR6227, MC3405 |
NA |
Colorectal Cancer |
Oncology |
PDX |
Preclinical pharmacology modeling of chimeric antigen receptor T therapies |
2021 |
NA |
NA |
NA |
NA |
Immuno-Oncology |
CDX, GEMM, HuCell, HuGEMM, Humanized models, MiXeno, MuPrime, Organoids, PDX, Sygeneic |
Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and L-lactide with controlled tensile properties and hydrophilicity. |
2002 |
M Maria Ryner, AC Ann-Christine AlbertssonM Maria Ryner , et al. |
AD0344 |
NA |
Acute Graft versus Host Disease |
NA |
CDX |
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib |
2018 |
NA |
CR1520, CR2502, CR2518, CR2520 |
NA |
Colorectal Cancer |
Oncology |
PDX |
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies |
2020 |
NA |
CR2518 |
ADC - Colorectal Cancer |
Colorectal Cancer |
Oncology |
PDX |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants |
2019 |
NA |
NA |
NA |
GIST |
Oncology |
PDX |
Robotic Radical Cystectomy Outcomes after Intervention for Prostate Cancer. |
2021 |
NH Neel H Patel, G Gus Miranda, J Jie Cai, MM Mihir M Desai, I Inderbir Gill, M Monish AronNH Neel H Patel , et al. |
NA |
NA |
NA |
NA |
CDX, HuCell |
Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies |
2022 |
NA |
NA |
NA |
Lymphoma |
Oncology |
Cell lines |
Selective RET kinase inhibition for patients with RET-altered cancers |
2018 |
NA |
CR2518, CR2545 |
ADC - Colorectal Cancer, NSCLC- Lung Cancer |
Colorectal Cancer |
Oncology |
PDX |
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT |
2017 |
NA |
LY0257, LY2298 |
B cell lymphoma - Lymphoma, B cell lymphoma (ABC/GCB, MYD88 L265P) - Lymphoma, NHL - Lymphoma, NHL (DLBCL, ABC) - Lymphoma |
Lymphoma |
Oncology |
PDX |
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment |
2001 |
NA |
NA |
NA |
NA |
Immuno-Oncology |
HuCell, HuGEMM |
Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function |
2015 |
NA |
CR2506, CR3150 |
ADC, mucinous adenocarcinoma - Colorectal Cancer, Adenocarcinoma - Colorectal Cancer |
Colorectal Cancer |
Oncology |
PDX |
The design, analysis and application of mouse clinical trials in oncology drug development |
2019 |
S Sheng Guo, X Xiaoqian Jiang, B Binchen Mao, QX Qi-Xiang LiS Sheng Guo , et al. |
AD0484, AD10272, AL5511, BL3249 |
ADC - Bladder Cancer, Astrocytoma - Brain Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer, Transition cell carcinoma - Bladder Cancer |
Bladder Cancer, Brain Cancer |
Immuno-Oncology, Inflammation |
CDX, HuGEMM, MiXeno |
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity |
2018 |
DAR Daniel A R Heisey, TL Timothy L Lochmann, KV Konstantinos V Floros, CM Colin M Coon, KM Krista M Powell, S Sheeba Jacob, ML Marissa L Calbert, MS Maninderjit S Ghotra, GT Giovanna T Stein, YK Yuki Kato Maves, SC Steven C Smith, CH Cyril H Benes, JD Joel D Leverson, AJ Andrew J Souers, SA Sosipatros A Boikos, AC Anthony C FaberDAR Daniel A R Heisey , et al. |
SA10233 |
Ewing's Sarcoma - Sarcoma |
Sarcoma |
Oncology |
PDX |
The Immune Landscape of Cancer |
2019 |
V Vésteinn Thorsson, DL David L Gibbs, SD Scott D Brown, D Denise Wolf, DS Dante S Bortone, TH Tai-Hsien Ou Yang, E Eduard Porta-Pardo, GF Galen F Gao, CL Christopher L Plaisier, JA James A Eddy, E Elad Ziv, AC Aedin C Culhane, EO Evan O Paull, IKA I K Ashok Sivakumar, AJ Andrew J Gentles, R Raunaq Malhotra, F Farshad Farshidfar, A Antonio Colaprico, JS Joel S Parker, LE Lisle E Mose, NS Nam Sy Vo, J Jianfang Liu, Y Yuexin Liu, J Janet Rader, V Varsha Dhankani, SM Sheila M Reynolds, R Reanne Bowlby, A Andrea Califano, AD Andrew D Cherniack, D Dimitris Anastassiou, D Davide Bedognetti, Y Younes Mokrab, AM Aaron M Newman, A Arvind Rao, K Ken Chen, A Alexander Krasnitz, H Hai Hu, TM Tathiane M Malta, H Houtan Noushmehr, CS Chandra Sekhar Pedamallu, S Susan Bullman, AI Akinyemi I Ojesina, A Andrew Lamb, W Wanding Zhou, H Hui Shen, TK Toni K Choueiri, JN John N Weinstein, J Justin Guinney, J Joel Saltz, RA Robert A Holt, CS Charles S Rabkin, , AJ Alexander J Lazar, JS Jonathan S Serody, EG Elizabeth G Demicco, ML Mary L Disis, BG Benjamin G Vincent, I Ilya ShmulevichV Vésteinn Thorsson , et al. |
AD0484, AL5511, BL3249 |
NA - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer |
Bladder Cancer |
Oncology |
CDX, HuCell |
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients |
2019 |
NA |
LU1147, LU11693, LU2512, LU6405 |
NSCLC- Lung Cancer |
Lung Cancer |
Immuno-Oncology, Oncology |
PDX |
Transcriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese population |
2020 |
Q Qiang Zhao, J Jia Xue, B Baoan Hong, W Wubin Qian, T Tiezhu Liu, B Bin Fan, J Jie Cai, Y Yongpeng Ji, J Jia Liu, Y Yong Yang, Q Qixiang Li, S Sheng Guo, N Ning ZhangQ Qiang Zhao , et al. |
NA |
CCRCC - Kidney Cancer |
Kidney Cancer |
Immuno-Oncology, Oncology |
PDX |
Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development. |
2022 |
R Rajendra Kumari, X Xiaoxi Xu, HQ Henry Qi-Xang LiR Rajendra Kumari , et al. |
NA |
NA |
NA |
NA |
Organoids |
Tumor Purity in Preclinical Mouse Tumor Models |
2022 |
NA |
NA |
NA |
NA |
Immuno-Oncology, Oncology |
PDX, Sygeneic |
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression |
2017 |
TL Timothy L Lochmann, KV Konstantinos V Floros, M Mitra Naseri, KM Krista M Powell, W Wade Cook, RJ Ryan J March, GT Giovanna T Stein, P Patricia Greninger, YK Yuki Kato Maves, LR Laura R Saunders, SJ Scott J Dylla, C Carlotta Costa, SA Sosipatros A Boikos, JD Joel D Leverson, AJ Andrew J Souers, GW Geoffrey W Krystal, H Hisashi Harada, CH Cyril H Benes, AC Anthony C FaberTL Timothy L Lochmann , et al. |
LU5263 |
SCLC - Lung Cancer |
Lung Cancer |
Oncology |
PDX |